Validation of cancer-type dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.

More about this publication

Annals of oncology : official journal of the European Society for Medical Oncology
  • Publication date 01-08-2022

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.